PSP Research’s Structure Therapeutics GPCR Stock Holding History

PSP Research’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,719	Closed	-$467K	–	89
2025 Q4	$467K	Buy	+6,719	New	+$274K	0.41%	81

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

PSP Research's GPCR Position: Q1 2026 in Review

PSP Research sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 6,719 shares — an estimated $467K sold.

PSP Research first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $467K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

PSP Research reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
PSP Research sold 6,719 Structure Therapeutics shares in Q1 2026, an estimated $467K.
PSP Research first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
PSP Research's Structure Therapeutics position peaked at $467K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.